. Admitted with unwitnessed fall and right hip pain. 2. New findings on XR chest concerning for infection vs malignancy. CT TAP noted: Multiple rounded pulmonary nodules are noted throughout both lungs, in keeping with multiple pulmonary metastases. No focal pulmonary mass lesion is demonstrated. There is no evidence of significant mediastinal or hilar lymphadenopathy. Small bilateral basal pleural effusions are noted, likely reactive. Within the abdomen, normal appearances of the liver, spleen, both kidneys and adrenal glands. No biliary tract pathology is identified. The pancreas is normal apart from 2.1 cm diameter low attenuation lesion within the pancreatic neck which is suspicious of an IPNM type lesion. The stomach is poorly distended and therefore has not been adequately assessed. The abdominal aorta is calcified and atheromatous, but not aneurysmal. There is no para-aortic, pelvic or mesenteric lymphadenopathy. No gross small or large bowel pathology is identified on this unprepared study. Faecal impaction is noted within the rectum, though there is no current evidence of stercoral ulceration or perforation. There is no peritoneal free gas, free fluid or collection. The urinary bladder is empty as it is catheterized. No lytic, sclerotic or destructive skeletal lesion to suggest the presence of any skeletal metastases. Conclusion: Pulmonary appearances are suspicious of extensive pulmonary metastases. No clear primary malignancy has been demonstrated. A lesion within the pancreatic neck is unlikely to be the source of multiple pulmonary metastases. You may wish to consider discussion at the HPB MDT. psa 59
Reading File
Finding Sources
Finding Sources
Searching PubMed
prostate cancer pulmonary metastases PSA elevated unknown primary
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Searching PubMed
metastatic prostate cancer PSA 59 treatment castration sensitive 2024
I now have solid material to construct a thorough clinical analysis. Let me compile the full response.
Clinical Analysis: Unwitnessed Fall, Right Hip Pain, Incidental CT TAP Findings, PSA 59
1. The Most Likely Diagnosis: Metastatic Prostate Cancer
The clinical picture strongly points to de novo metastatic prostate cancer as the unifying diagnosis:
- PSA of 59 ng/mL is markedly elevated. In a man (sex is implied by PSA), a PSA >10 raises strong suspicion for prostate cancer, and a PSA >20 correlates with high risk of metastatic disease. A PSA of 59 without a known prior prostate cancer diagnosis is highly significant.
- Multiple bilateral rounded pulmonary nodules - the CT TAP describes these as "in keeping with multiple pulmonary metastases." Prostate cancer is a recognised cause of pulmonary metastases, though less common than breast, colorectal, or renal primaries. Prostate lung metastases classically appear as multiple bilateral nodules, consistent with this CT description (Prostate Cancer Lung Metastasis review, PMID: 38893199).
- No primary lesion identified on CT TAP - CT does not image the prostate adequately for cancer diagnosis. Prostate cancer is not visible on CT unless the gland is grossly enlarged or there is local extension. The absence of an identified primary on CT does not exclude prostate cancer.
- No skeletal metastases on CT - Notably, no lytic/sclerotic lesions are seen. However, CT has limited sensitivity compared to bone scan or PSMA PET/CT for skeletal metastases. Some prostate metastases, particularly early or predominantly visceral/pulmonary, may not yet show bony disease.
- Harrison's Principles explicitly notes: "Blastic bone-only metastasis is a rare presentation, and elevated serum PSA or tumor staining with PSA may provide confirmatory evidence of prostate cancer in these patients. Those with elevated levels are candidates for hormonal or other therapy for prostate cancer, although it is important to rule out other primary tumors (lung most common)." - Harrison's Principles of Internal Medicine 22E, p. 778
2. Differential Diagnoses to Consider
| Diagnosis | For | Against |
|---|---|---|
| Metastatic prostate cancer | PSA 59, bilateral pulmonary nodules, male | No bony mets on CT, no identified prostate primary |
| Primary lung cancer with PSA-secreting features | Bilateral nodules | PSA 59 is much higher than seen in ectopic PSA secretion from lung |
| IPMN with malignant transformation | Pancreatic neck lesion | CT specifically states IPMN-type; IPMN rarely causes multiple pulmonary metastases without peritoneal or hepatic spread; no liver/nodal disease |
| Carcinoid/Neuroendocrine tumour | Multiple bilateral nodules | No hepatic mets, no ascites, PSA not explained |
| Lymphoma | Bilateral pulmonary lesions | No mediastinal/hilar lymphadenopathy, PSA 59 not consistent |
3. The Pancreatic Lesion
The CT identifies a 2.1 cm low-attenuation lesion in the pancreatic neck, described as suspicious for an IPMN-type lesion. The radiology report itself notes this is "unlikely to be the source of multiple pulmonary metastases" and recommends HPB MDT discussion.
IPMN (Intraductal Papillary Mucinous Neoplasm) is a cystic pancreatic lesion with a spectrum of biological behaviour:
- Branch-duct IPMNs are typically slow-growing and low-risk
- Main-duct IPMNs carry higher malignant risk (~50-70%)
- A 2.1 cm lesion in the neck warrants further characterisation with MRI/MRCP and EUS (endoscopic ultrasound) to assess ductal communication, presence of mural nodules, and solid components
This lesion is likely an incidental finding separate from the metastatic process. HPB MDT referral is appropriate once the primary oncological issue (prostate cancer) is addressed.
4. The Right Hip - Fracture vs. Metastatic Disease
The patient was admitted with an unwitnessed fall and right hip pain. Key considerations:
- Hip fracture must be excluded - even in the absence of visible bony metastases on CT, obtain AP pelvis and lateral hip X-rays. If inconclusive and clinical suspicion is high, MRI pelvis is the gold standard for occult hip fracture.
- Pathological fracture risk - a PSA of 59 with widespread pulmonary metastases raises concern that a fall may have been precipitated by pain from an underlying skeletal lesion not yet visible on CT. Bone scan or PSMA PET/CT would be more sensitive.
- The fall itself may also be multifactorial in an older patient (postural hypotension, medications, deconditioning).
5. Immediate Management Plan
Investigations - in priority order:
- DRE (Digital Rectal Examination) - assess prostate size, consistency, nodularity
- Urology/Oncology referral - urgent
- Prostate biopsy - TRUS-guided or MRI-targeted biopsy to confirm histology, Gleason grade
- Multiparametric MRI prostate - for local staging
- PSMA PET/CT - now the preferred staging modality for metastatic prostate cancer; highly sensitive for nodal, visceral, and skeletal disease even at PSA levels <10. Far superior to conventional bone scan. The EAU 2024 guidelines recommend PSMA PET/CT for staging of high-risk prostate cancer.
- Bone scan - if PSMA PET/CT not immediately available
- Testosterone level - baseline prior to any hormonal manipulation
- Hip films / MRI hip - to investigate the mechanism of fall and exclude fracture or metastatic bony disease
- MRI/MRCP pancreas - for the IPMN characterisation (deferred until cancer workup progressed)
- EUS + FNA of pancreatic lesion - in due course at HPB MDT
Bloods:
- FBC, U&E, LFTs, bone profile (Ca2+, ALP - ALP raised in osteoblastic bony disease), LDH
- Repeat PSA (confirm)
- Testosterone
- CA 19-9 (for pancreatic lesion assessment)
6. Oncological Treatment - Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Assuming biopsy confirms prostate adenocarcinoma:
The standard of care as per the EAU 2024 guidelines (PMID: 38688773) and Goldman-Cecil Medicine is androgen deprivation therapy (ADT) combined with intensification:
- ADT backbone: GnRH agonist (e.g. leuprolide, goserelin) or GnRH antagonist (e.g. degarelix, relugolix)
- Intensification (doublet or triplet therapy based on volume of disease):
- For high-volume disease (4+ bone lesions or visceral metastases): ADT + docetaxel, or ADT + abiraterone/enzalutamide/apalutamide/darolutamide
- Triplet therapy (ADT + docetaxel + abiraterone) is supported by the PEACE-1 trial data
- If pulmonary disease is confirmed as visceral metastases from prostate cancer, this qualifies as high-volume disease
Goldman-Cecil notes: "the addition of docetaxel to androgen-deprivation therapy in patients with hormone-sensitive disease extends median overall survival by 17 months compared with androgen therapy alone in patients who have high-volume disease, defined by presence of visceral metastasis or four or more bone lesions." - Goldman-Cecil Medicine, International Edition
The ASCO 2025 guideline update on mCRPC (PMID: 40315400) and the French AFU 2024-2026 guidelines (PMID: 39581665) further support sequential therapy planning based on molecular status (BRCA1/2, MSI-H, etc.).
7. MDT Involvement
This patient requires coordinated input from:
| Speciality | Role |
|---|---|
| Urology / Uro-oncology | Prostate biopsy, staging, treatment initiation |
| Medical Oncology | Systemic therapy planning |
| Radiology | PSMA PET/CT, MRI prostate/hip |
| HPB Surgery / Gastroenterology | IPMN characterisation and surveillance |
| Orthopaedics | Hip fracture exclusion/management |
| Palliative Care | Early referral for symptom management given metastatic disease |
| Geriatrics | If elderly patient - falls assessment, functional status, frailty scoring |
Summary
Working diagnosis: De novo metastatic castration-sensitive prostate cancer (mCSPC) presenting as bilateral pulmonary metastases with a PSA of 59. The pancreatic neck IPMN is most likely an incidental finding. The fall/right hip pain needs fracture exclusion and an assessment of whether a pathological process contributed. Urgent urology referral, prostate biopsy, and PSMA PET/CT are the most important next steps. Treatment with ADT + intensification agent should follow confirmed histology.
what tumor markers can be sen tin nhs inpatient
Searching the Web
NHS tumour markers available inpatient blood tests UK biochemistry laboratory
Finding Sources
Reading Web Page
https://www.nn.nhs.scot/clinicalbiochemistry/wp-content/uplo…
Finding Sources
tumor markers for this patient that can be sent in nhs
For this specific patient (male, multiple pulmonary metastases, PSA 59, pancreatic neck lesion), here are the relevant tumour markers available in NHS inpatient biochemistry:
Tumour Markers to Send - This Patient
🔴 Priority / Most Relevant
| Marker | Relevance to This Patient | Available NHS Inpatient? |
|---|---|---|
| PSA (already 59) | Confirm prostate cancer primary - repeat to document baseline | ✅ All NHS trusts |
| CA 19-9 | Pancreatic IPMN/neck lesion - raised in pancreatic adenocarcinoma, biliary, colorectal | ✅ Most NHS trusts |
| CEA | Colorectal, lung, pancreatic, gastric cancer - helps rule out CUP differentials | ✅ Most NHS trusts |
| AFP (alpha-fetoprotein) | Hepatocellular carcinoma, germ cell tumour (less likely here but part of CUP screen) | ✅ Most NHS trusts |
| LDH | Lymphoma, widespread metastatic disease - also a prognostic marker in mets | ✅ All NHS trusts (often on standard bloods) |
🟡 Send If Clinical Picture Warrants
| Marker | Relevance | Notes |
|---|---|---|
| Beta-hCG | Germ cell tumour (part of standard CUP screen in a man with pulmonary nodules) | ✅ Available - request as part of GCT screen |
| CA 15-3 | Breast cancer (less relevant in male) | ✅ Available but low yield here |
| Chromogranin A | Neuroendocrine tumour - consider if carcinoid/NET still on differential | ✅ Most NHS trusts - often sent to specialist lab |
| Calcitonin | Medullary thyroid cancer | ✅ Available but low yield here |
| Serum protein electrophoresis / paraprotein screen | Myeloma if bony disease suspected | ✅ All NHS trusts |
⚡ Practically - What to Actually Request for This Patient
Given the working diagnosis of metastatic prostate cancer (PSA 59) with possible CUP workup and pancreatic IPMN, request:
- PSA - already done, but document as baseline pre-treatment
- CA 19-9 - for the pancreatic lesion
- CEA - part of CUP screen, also relevant to exclude colorectal primary
- AFP + beta-hCG - complete the CUP/germ cell screen
- LDH - prognostic marker for metastatic disease
- Chromogranin A - if neuroendocrine is still considered (NET can cause bilateral pulmonary nodules)
Important NHS-Specific Notes
- PSA is available same-day at virtually all NHS trusts
- AFP, CEA, CA 19-9 are available at most DGH labs; some require sending to a regional biochemistry lab (results in 24-48h)
- AFP, hCG, CEA, CA 15-3, CA 19-9 per NHS Scotland guidance should be requested "as advised by the specialist secondary care team" - as an inpatient under oncology/urology, you are covered to request these
- Chromogranin A may need to go to a specialist/regional lab - check your local lab handbook
- Write "? metastatic malignancy - CUP screen, known PSA 59" as the clinical indication on the request form - this prevents rejection and aids lab interpretation
- Avoid sending a blanket panel without clinical indication - labs may reject or query them
What These Results Will Tell You
| Result Pattern | Interpretation |
|---|---|
| PSA high + others normal | Strongly supports prostate primary |
| CA 19-9 very elevated (>500) | Raises concern for malignant transformation of IPMN or separate pancreatic primary |
| CEA markedly elevated | Consider colorectal or lung primary contributing |
| AFP + hCG raised | Germ cell tumour - changes management completely |
| LDH very high | Suggests high tumour burden / rapid turnover |
| Chromogranin A raised | Consider NET as primary - important as management differs |
In this patient, the most likely outcome is PSA dominant with other markers relatively normal, which would consolidate the diagnosis of prostate cancer as the primary. The CA 19-9 result alongside the pancreatic lesion will help guide whether urgent HPB MDT referral needs escalating.
This is a shared conversation. Sign in to Orris to start your own chat.